Literature DB >> 9032258

Costimulation by B7-1 and LFA-3 targets distinct nuclear factors that bind to the interleukin-2 promoter: B7-1 negatively regulates LFA-3-induced NF-AT DNA binding.

E Parra1, M Varga, G Hedlund, T Kalland, M Dohlsten.   

Abstract

We have characterized the regulation of nuclear factors involved in transcriptional control of the interleukin-2 (IL-2) promoter-enhancer activity in Jurkat T cells stimulated with superantigen presented on HLA-DR transfectants combined with the ligands LFA-3 (CD58) and B7-1 (CD80). Gel shift analyses showed that NF-AT was strongly induced in LFA-3-costimulated Jurkat T cells, suggesting that NF-AT is a key target nuclear factor for the CD2-LFA-3 pathway. Studies using HLA-DR-B7-1-LFA-3 triple transfectants showed that the LFA-3-induced NF-AT DNA binding activity was negatively regulated by B7-1 costimulation. In contrast, induction of a CD28 response complex containing only c-Rel proteins was seen after B7-1 costimulation. Both LFA-3 costimulation and B7-1 costimulation induced the AP-1 and NF-kappaB nuclear factors. Distinct compositions of the NF-AT complexes were seen in B7-1- and LFA-3-costimulated cells. LFA-3 induced primarily Jun-D, Fra-1, and Fra-2, while B7-1 induced June-D-Fos complexes. In contrast, AP-1 and NF-kappaB complexes induced in B7-1- and LFA-3-costimulated T cells showed similar contents. Transient transfection of Jurkat T cells with a construct encoding the IL-2 enhancer-promoter region (position -500 to +60) linked to a luciferase reporter gene revealed that B7-1 costimulation was required to induce strong transcriptional activity. Combined B7-1-LFA-3 costimulation resulted in a synergistic increase in IL-2 transcriptional activity. Multimers of the AP-1, NF-AT, NF-kappaB, and CD28 response elements showed distinct kinetics and activity after LFA-3 and B7-1 costimulation and revealed that B7-1 and LFA-3 converge to superinduce transcriptional activity of the AP-1, NF-AT, and CD28 response elements. Transcriptional studies with an IL-2 enhancer-promoter carrying a mutation in the CD28 response element site revealed that the activity was reduced by 80% after B7-1 and B7-1-LFA-3 costimulation whereas the transcriptional activity induced by LFA-3 was unaffected. Our data strongly suggest a selectivity in induction of nuclear factors by the CD2-LFA-3 and CD28-B7-1 pathways. This selectivity may contribute to regulation of the levels of IL-2 induced by LFA-3 and B7-1 costimulation and favor autocrine and paracrine T-cell responses, respectively.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032258      PMCID: PMC231856          DOI: 10.1128/MCB.17.3.1314

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  58 in total

1.  Immunogenicity signals 1,2,3 ... and 0.

Authors:  C Janeway
Journal:  Immunol Today       Date:  1989-09

2.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-08-29       Impact factor: 41.582

3.  Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells.

Authors:  E Schreiber; P Matthias; M M Müller; W Schaffner
Journal:  Nucleic Acids Res       Date:  1989-08-11       Impact factor: 16.971

4.  Interaction of CD2 with its ligand, LFA-3, in human T cell proliferation.

Authors:  B E Bierer; J Barbosa; S Herrmann; S J Burakoff
Journal:  J Immunol       Date:  1988-05-15       Impact factor: 5.422

5.  Lymphocyte activation and effector functions. Editorial overview. The role of cell surface molecules.

Authors:  C A Janeway; P Golstein
Journal:  Curr Opin Immunol       Date:  1993-06       Impact factor: 7.486

6.  Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor.

Authors:  P Angel; M Imagawa; R Chiu; B Stein; R J Imbra; H J Rahmsdorf; C Jonat; P Herrlich; M Karin
Journal:  Cell       Date:  1987-06-19       Impact factor: 41.582

7.  Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements.

Authors:  W Lee; P Mitchell; R Tjian
Journal:  Cell       Date:  1987-06-19       Impact factor: 41.582

8.  Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway.

Authors:  T Lindstein; C H June; J A Ledbetter; G Stella; C B Thompson
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

9.  Identification of a putative regulator of early T cell activation genes.

Authors:  J P Shaw; P J Utz; D B Durand; J J Toole; E A Emmel; G R Crabtree
Journal:  Science       Date:  1988-07-08       Impact factor: 47.728

10.  Characterization of antigen receptor response elements within the interleukin-2 enhancer.

Authors:  D B Durand; J P Shaw; M R Bush; R E Replogle; R Belagaje; G R Crabtree
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272

View more
  5 in total

Review 1.  Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment.

Authors:  D J Naisbitt; S F Gordon; M Pirmohamed; B K Park
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

2.  The detection of sLFA-3 in plasma of patients with hemorrhagic fever with renal syndrome.

Authors:  Ming Xie; Ping Chen; Lin-Jing He; Bao-Tai Qi; Ping Wang; Xiao-Fang Wang; Hui-Xun Ren
Journal:  Clin Exp Med       Date:  2008-09-27       Impact factor: 3.984

3.  A self-inactivating retrovector incorporating the IL-2 promoter for activation-induced transgene expression in genetically engineered T-cells.

Authors:  Diana E Jaalouk; Laurence Lejeune; Clément Couture; Jacques Galipeau
Journal:  Virol J       Date:  2006-11-21       Impact factor: 4.099

Review 4.  CD2 Immunobiology.

Authors:  Christian Binder; Filip Cvetkovski; Felix Sellberg; Stefan Berg; Horacio Paternina Visbal; David H Sachs; Erik Berglund; David Berglund
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

Review 5.  CD58 Immunobiology at a Glance.

Authors:  Yalu Zhang; Qiaofei Liu; Sen Yang; Quan Liao
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.